| |
LPV/r + TDF
(n=72) |
LPV/r + 2 NRTIs (n=80) |
| treatment exposure (weeks) |
54.33 |
54.00 |
| any AE |
61 (84.7%) |
67 (83.8%) |
| any drug-related AE |
39 (54.2%) |
52 (65.0%) |
| any serious AE |
10 (13.9%) |
7 (8.8%) |
| any drug-related serious AE |
0 |
2 (2.5%) |
| any AE causing D/C |
9 (12.5%) |
6 (7.5%) |
any AE causing death
Dyspnea and chest pain
Suspect lymphoproliferative disorder
|
2 (2.8%)
1
1 |
0 |
| GI Disorders |
37 (51.4%) |
33 (41.3%) |
| Diarrhoea |
28 (38.9%) |
23 (28.8%) |
| Nausea |
6 (8.3%) |
6 (7.5%) |
| Vomiting |
7 (9.7%) |
6 (7.5%) |
| General disorders |
10 (13.9%) |
20 (25%) |
| Fever |
6 (8.3%) |
12 (15.0%) |
| Asthenia |
3 (4.2%) |
8 (10.0%) |
| Other |
|
|
| Headache |
3 (4.2%) |
6 (7.5%) |
| Cough |
5 (6.9%) |
7 (8.8%) |
| METABOLIC DISORDERS |
14 (19.4%) |
23 (28.8%) |
| Dyslipidemia |
1 (1.4%) |
4 (5.0%) |
| Hypertriglyceridemia |
9 (12.5%) |
14 (17.5%) |
| Total cholesterol Grade III-IV |
3 (4.2%) |
7 (8.8%) |
| Triglycerides Grade III-IV |
5 (6.9%) |
9 (11.3%) |
AE, Adverse Event; D/C, discontinuation; LPV/r, Lopinavir/ritonavir; NRTI,
Nucleoside Reverse Transcriptase Inhibitor; TDF, Tenofovir Disoproxyl Fumarate. |